Background: We describe the surgical treatment, outcome and long-term survival of patients with multiple myeloma (MM) in response to conventional (CC) or high-dose (HDT) chemotherapy. Patients and methods: Eighty-four patients diagnosed with MM were recruited for the study (51 male, 33 female; median age 62 years) and consecutively surgically treated in a single institution during a 12-year period. The main end point of the study was overall survival after surgery. Cox regression analysis was used to estimate the effect of factors that may predict survival. Results: Spinal surgery was performed in 54 cases, and 30 patients were surgically treated at the extremities. The post-surgical complication rate was low (17%; 14/84 patients). The median overall survival time was 47 months. Patients receiving HDT had a longer 5-year overall survival rate than patients receiving CC (51% versus 33%). Univariate predictors of mortality included age >65 years [risk ratio (RR) 1.62; P = 0.023], osteolyses in long weight-bearing bones (RR 2.23; P = 0.007) and an elevated C-reactive protein level >5 mg/l (RR 1.82; P = 0.016); the latter remained significant as a predictor in multivariate analysis (RR 2.66; P = 0.0209). Conclusions: Given the high number of patients reaching 5-year overall survival and the low postsurgery complication rate, surgery should pursue a long-term stable reconstruction of the affected bone.
Introduction
The major clinical manifestation of multiple myeloma (MM) results from bone destruction. Sixty to eighty per cent of newly diagnosed patients present with clinical symptoms related to bone disease such as bone pain, hypercalcaemia, fractures and spinal cord compression [1] . The surgical outcome of lytic bone lesions in MM is often compared with that of bone metastases. The overall survival time in metastatic bone disease ranges between 6 and 22 months [2, 3] depending on the type of primary tumour. The prognosis for patients with MM has improved significantly in recent years. Owing to advances in systemic therapy, e.g. high-dose chemotherapy (HDT) and peripheral blood stem cell transplantation (PBSCT), overall survival rates of >5 years can be achieved [4, 5] .
To date, only a few studies have been published reporting the clinical course of patients after surgical treatment of MM [6 -8] . These studies have dealt with small numbers of patients and did not include an assessment of preoperative biochemical findings that are of prognostic significance for MM patients.
In this explorative study we analysed surgically treated patients with MM. Our primary aim was to describe the surgical treatment, management and outcomes in response to conventional chemotherapy (CC) or HDT, as well as to assess long-term survival. Multivariate analysis was used to estimate the effect of factors, e.g. serum lactate dehydrogenase (LDH), serum b 2 -microglobulin level (B2M), C-reactive protein (CRP) and performance status, measured at the time of surgery that may function as predictors of survival.
Material and methods Patients
Eighty-four patients with MM who were consecutively surgically treated in the authors' institution between January 1990 and March 2002 were retrospectively recruited. The median age at surgery was 62 years (range 29-90). Fifty patients (60%) were <65 years old. Patient survival was followed up for a median time of 46 months. The baseline characteristics of patients are summarised in Table 1. 30 patients. No chemotherapy was administered to 16 patients. All patients received supportive care measures with bisphosphonates, which is currently the therapy of choice in MM patients with hypercalcaemia.
Most of the patients were mobile and their overall functional status was equivalent to a Eastern Cooperative Oncology Group (ECOG) performance status of 1 or 2 [9] . Four of 84 patients (5%) were capable of only limited self-care and were confined to a bed or chair for >50% of waking hours. One patient was completely disabled.
Methods
The patients were retrospectively assessed for clinical stage according to Durie and Salmon [10] and for established biochemical markers [11] , i.e. B2M, CRP and LDH, at surgery. Cytogenetic abnormalities were not addressed.
Particular details of surgical and oncological outcome were obtained during physical examination or retrieved from the Orthopaedic Oncology Cancer Registry that is maintained at the authors' institution.
The indication for surgical treatment at the extremities included lesions with elevated fracture risk according to Mirels' Scoring System [12] and known fractures. Indication for surgical intervention at the vertebral column included progressive neurological impairment (complete or incomplete neurological deficits, corresponding to Frankel grade A-D [13] assessing sensory and motor function) or severe vertebral body lesions. Irrespective of the anatomical site, surgical intervention was indicated for intractable pain. The neurological outcome was assessed prior to and 1 month after surgery.
Based on Ruggieri et al.'s classification [14] , post-treatment complications were categorised as 'minor', not requiring surgery (grade I or II), or 'major', requiring surgery (grade III-V). Complications were categorised into four groups. Type A (local wound complications): wound infection, fistula, seroma, haematoma, prolonged wound healing and skin necrosis. Type B (implant failure): septic or aseptic endoprosthetic or internal fixation device loosening, dislocation, luxation, implant fracture, pseudarthrosis. Type C (non-orthopaedic complications): pulmonary embolism, haemodynamic failure, deep venous thrombosis. Type D (others): perioperative nerve injuries, differences in leg length, lymphoedema, decubitus ulcer.
Statistical methods
Descriptive statistics were performed for all variables. Categorical data are expressed as percentages with associated 95% confidence intervals (CIs). Continuous data are expressed as medians with 5th and 95th percentiles. Observed overall survival estimates were based on Kaplan-Meier survival curves [15] . Univariate and multivariate Cox regression analyses were performed to identify effects of factors that might predict survival [16] . Risk ratios were estimated and given with 95% CIs. On account of the observational character of this study, which included patients treated from 1990 to 2002, a stratified Cox proportional hazard model was calculated standardising for differences in adjuvant treatment such as conventional or HDT and PBSCT in the subgroups. Complete sets of data were available for 72 patients (86%) and were included in the analysis. All calculations for significance were two-sided and were performed at the 5% level. The statistical software used for the calculation was SAS, version 8.2 (SAS Inc., Cary, NC, USA).
For power calculations, a rule of thumb for regression equation was applied, proposing that when using six or more predictors, an absolute minimum of 10 participants per independent predictor is appropriate [17] .
Results

Patient characteristics
At first presentation in the department of orthopaedic surgery, the patients' most common complaints were bone pain. In 35 patients, compression fractures of the thoracic or lumbar vertebral body and, in 10 patients, pathological fractures of the long bones led to the diagnosis of MM.
Anatomical sites of bone lesions were non-extremities (29 thoracic vertebrae, 14 lumbar vertebrae, six cervical vertebrae, three costa, one sternum, one os ilium) or extremities (17 femur, 11 humerus, one ulna, one tibia).
Primary indications for surgery of long bones were pathological fractures (15 femur, 11 humerus, one ulna and one tibia) or an impending fracture risk with a Mirels score >8 (two femur). Fifteen of the patients underwent local irradiation prior to surgery. Surgery of the vertebral column was indicated for progressive neurological deficiency (18 thoracic vertebrae, five lumbar vertebrae) or impending instability (six cervical vertebrae, 11 thoracic vertebrae and nine lumbar vertebrae). Indications for surgery of the thoracic skeleton or the pelvic bone were pathological fractures (two costa), pain (one sternum, one costa) and an impending fracture (one os ilium). Neurological impairments were classified according to Frankel A (one), Frankel B (three), Frankel C (six) and Frankel D (12). The serum B2M level ranged between 1.3 and 11.2 mg/l (median 5.5) at surgery. In 40 patients (55%), the B2M level exceeded 2.5 mg/l; three (8%) of these patients had values >3 mg/l and 25 (62%) had >3.5 mg/l. The median CRP level was 3.6 mg/l (0.2-303) and was above the standardised upper normal limit of 5 mg/l in 14 patients (16%). An elevated LDH level >240 U/l was found in seven patients (9.7%).
Age-related chronic health problems (11 heart disease, three pulmonary disease, five diabetes, 11 hypertension) reflect the general health status of the study population.
Fifteen patients with single thoracic or lumbar vertebral body lesions were treated by a combined approach with anterior resection and posterior instrumentation [18, 19] . When contiguous vertebral bodies were involved or the patients' general health status was reduced, a one-stage posterior decompression -stabilisation procedure was performed (n = 18) [8, 20] . Tumour surgery in the cervical vertebrae was performed only by ventral decompression and stabilisation (n = 6). Owing to the risk of vertebral instability, decompressive laminectomy alone was not indicated [21, 22] .
Femoral or humeral articular or metaphyseal fractures were replaced with cemented endoprostheses. In the subtrochanteric region long-stem femoral endoprostheses were used (n = 8), in one case following a failed proximal femoral nail. In 16 patients diaphyseal osteolytic lesions were reconstructed with compound osteosynthesis.
The overall complication rate following surgery was 17% (14/84). Two patients had more than one complication. Local wound complication (type A) occurred in six cases, predominantly following plate osteosynthesis. Three required re-operation. Implant failure (type B) was observed in five cases. One patient died during the first month after surgery due to heart failure. Other non-orthopaedic complications (type C) were pulmonary embolism (two) and venous thromboembolism (one) ( Table 2) .
Local recurrences occurred in five out of 84 patients (6%), four times following surgery of the vertebral column and once following internal hemipelvectomy. Forty-eight of 84 patients developed additional skeletal lesions during the course of the disease. The majority of these were locally irradiated; 14 needed surgical intervention.
Overall survival
Observed overall survival since diagnosis for surgically treated patients is shown in Figure 1 . Overall survival estimates at 1, 3, 5 and 10 years were 86.8%, 68%, 50% and 30.1%, respectively.
The median overall survival times for patients since surgery were 47 (±17) months. They were followed up for a mean of 3.5 years. The probability of surviving 1 year after surgery was 76%; 3-and 5-year survival probabilities were 59% and 40%, respectively.
Predictors of survival
Univariate regression analysis revealed significantly poorer predictive values for age >65 years [risk ratio (RR) 1.62; Improved 5-year overall survival rates were shown for patients treated with HDT and PBSCT compared with patients receiving CC or without chemotherapy (51% versus 33% and 25%, respectively) (Figures 2-4) . Stratified multivariate analysis estimated an elevated CRP level >5 mg/l as the only significant independent risk factor for mortality (P = 0.0209), with the risk of death increased to RR 2.6.
Discussion
Owing to a change in methodology from CC followed by HDT with PBSCT, a considerable improvement in overall survival could be achieved for patients with newly diagnosed MM [5] . Their actuarial survival rate is far better than for patients with bone metastases. This accounts for the fact that in myeloma patients requiring orthopedic surgery, a treatment option should be chosen that consists of a fit and stable reconstruction of the bone defects. Only few studies, which were quite small, have been published reporting the clinical course of patients surgically treated for MM [6] [7] [8] .
In this study population, presenting features, e.g. neurological impairments, prior to spinal surgery were more prevalent (22/49; 45%) than in other studies (6/27; 22%) [8] . However, 14 out of 49 patients (29%) showed improved neurological function after surgery, 10 of them following dorsal decompression and stabilisation. No patient developed progressive neurological impairment after surgery. Similar results were reported in patients following posterior decompression and stabilisation for metastatic spinal cord compression by Rompe et al. [23] . Other authors report neurological improvement in up to 81% of patients with spinal neoplasm following combined anterior -posterior approaches [19, 24] . Furthermore, from our own results we maintain that the prognosis for neurological recovery is adversely affected by both a greater degree and a longer duration of canal narrowing, indicating that patients may benefit from early decompression regardless of the chosen surgical procedure [25] .
The high benefit of surgery for patients with MM is further demonstrated by the low post-surgical complication rate. With 8% (4/49) it was lower than that reported for patients with metastases following surgery. There was no evidence of refractures in operated limbs. Pascal-Moussellard et al. [26] report a complication rate of 19% (17/145) following vertebral metastasis surgery. Even with an anterior -posterior approach, a complete resection in the vertebral column is not possible and is contraindicated for patients with a poor health status. In any case, radiation therapy for residual tumour following incomplete resection is performed, as the vertebral column is the location mostly affected by local recurrences (four out of five).
To date, there is no evidence from controlled clinical trials with a long-term follow-up to show to what extent percutaneous vertebroplasty/kyphoplasty may be considered as an additional therapeutic option for patients with lytic lesions due to MM, but early results are promising [27] . Based on this study, further outcome studies should be undertaken to evaluate the effectiveness of kyphoplasty.
The overall complication rate after reconstructive surgery at the extremities was low, except for compound plate osteosynthesis (three local wound complications, one implant failure). Despite the generally assumed immunodeficiency for patients with MM and reduced partial thromboplastin time in 22% of the patients, local wound complications or haematomas occurred in only six patients.
While univariate analyses revealed patient age >65 years, osteolyses in long weight-bearing bones and an elevated CRP >5 mg/l at surgery negatively predict survival, the application of HDT with PBSCT decreased the relative risk of death by an RR of 0.5.
In contrast to the proven high prognostic value of B2M at diagnosis, this value was not found to be significant. This might be due to the fact that B2M, which reflects the tumour mass, was assessed in response to CC or HDT, i.e. at the time of maximum tumour reduction in the patient. The negative effect of an increased CRP level before surgery on survival might be attributed to a disease progression as CRP is regulated by interleukin-6, a growth factor for MM [28] .
In earlier reports, the anatomical site of lytic bone lesions, Salmon-Durie stage III and advanced age were indicated as negative predictors for survival [11] . The 5-year actuarial survival rate for non-extremity location was 52 months versus extremity location 17 months (RR 2.0; P = 0.017). It can be assumed that plasma cells infiltrate first the axial skeleton, which leads to the compression of marrow. With increased cellular proliferation, extensive bone destruction, pathological fractures, hypercalcaemia and osteolyses in long weightbearing bones becomes evident, indicating an advanced stage of disease [29] . The Salmon -Durie stage could not be identified as having a significant prognostic value; however, stage III increased the risk of death to RR 2.2 (P = 0.126). Despite Figure 4 . Five-year overall survival estimates since surgery by high-dose chemotherapy/peripheral blood stem cell transplantation and conventional chemotherapy or without chemotherapy (51% versus 33% and 25%, P = 0.05).
the fact that some authors consider age to be a prognostic factor for survival in patients with MM [30] , we assume that the strong correlation between age >65 years and poor survival is partly accounted for by the fact that effective HDT and PBSCT were generally preserved in patients under the age of 65 years.
However, in multivariate analysis, stratified for HDT and PBSCT, the only independent predictor for survival that remained statistically significant was an elevated CRP >5 mg/l, with an increased risk for mortality of RR 2.6 (P = 0.0209). With the given 72 complete datasets that were included in the analyses and eight independent variables, small effects probably could not be detected.
Conclusions
This study confirmed improved long-term overall survival after diagnosis, especially for patients treated with HDT and PBSCT. The clinical implication of our findings, given the high percentage of patients reaching 5-year survival and the low post-surgery complication rate, is that the aim of surgery should be a fit and stable reconstruction of the affected bone.
Univariate predictors for mortality after surgery included age >65 years, osteolyses in long weight-bearing bones and an elevated CRP >5 mg/l before surgery. Although explorative in nature, based on these preliminary results, further investigation aiming to identify prognostic factors after surgical intervention for bone disease in MM, including kyphoplasty, should be undertaken.
